Pharmaceutical Packaging Market Intelligence: Size, Share and Growth Outlook Through 2031

Market Overview

Size, mix, and 2031 outlook

• Brevintel analysis values the market at USD 172.6 billion in 2025 ($172.6B), rising from USD 198 billion in 2026 to USD 405.1 billion in 2031 ($405.1B) at a 15.9% CAGR.
• A longer path lists USD 744.6 billion in 2035, so both the 2026–2031 card set ($172.6B, $405.1B, 15.9%) and the 2035 figure are retained.
• Primary packaging is the largest type at $122.07 billion in 2025 (70.4%) and is projected to $515.28 billion by 2035 at a 15.60% CAGR.
• Secondary packaging is the fastest type at a 17.10% CAGR from $34.12 billion in 2025 to $163.82 billion by 2035 as cartons and labels become traceability components.
• Tertiary packaging is expected to increase from $16.38 billion in 2025 to $65.53 billion by 2035 at a 14.98% CAGR, tracking pharmaceutical-output logistics.
• Rigid packaging generated $97.42 billion in 2025 (56.5%) and is forecast to reach $374.55 billion by 2035 at a 14.52% CAGR.
• Amcor plc led with over 3.5% market share in 2025 (3.46%); the top five collectively held 10.2%.
• People aged 60 years or older are projected to reach 1.4 billion by 2030, while those aged 80 years or over are expected to reach 426 million by 2050.

Compliance, biologics, and aging demand

• Aging populations raise demand for chronic-therapy packs that support repeated dispensing, clearer patient-use formats, and self-administered injectable delivery.
• U.S. current good manufacturing practice rules govern container and closure controls, making material specifications a manufacturing quality issue.
• The Drug Supply Chain Security Act (DSCSA) makes serialized data carriers, inspection, and data exchange integral to the commercial pack.
• In Europe, the Falsified Medicines Directive requires safety features on most prescription-medicine outer packs, linking carton design and tamper evidence to market access.
• Industry data suggests expansion will be led by packaging whose value is set by qualification, process integration, and compliance rather than material consumption alone.
• The gap is clearest between conventional oral-solid packs and sterile injectable systems that must manage drug-contact compatibility, closure integrity, and aseptic processing.
• Suppliers that combine containment expertise with high-speed inspection, traceability, and fill-finish compatibility are better placed than converters competing only on material cost.
• Ready-to-use vials, cartridges, and syringes reduce washing, depyrogenation, and sterilization work at fill-finish sites and raise the value of validated container platforms.

Market Dynamics

Drivers

• FDA container and closure requirements make material control, specifications, and quality systems non-discretionary for drug manufacturers.
• DSCSA package-level traceability extends those controls to serialized identifiers and interoperable transaction data that must print, inspect, and reconcile at line speed.
• The European safety-feature regime similarly requires a unique identifier and anti-tampering device on applicable prescription-medicine packs.
• Higher use of chronic therapies expands prescription cycles, while specialty therapies shift demand toward containers and delivery systems that need more extensive qualification.
• SCHOTT Pharma, Gerresheimer, and Stevanato Group formed the Alliance for RTU in October 2024 to promote broader adoption of ready-to-use containers.
• Nipro launched D2F glass vials in October 2024 using Stevanato Group EZ-fill technology in a pre-sterilized nest-and-tub format for automated fill-finish.
• Contract manufacturers need containers that can be integrated into multiple customer programs without rebuilding every upstream handling step.
• For suppliers, the commercial opportunity is longer qualification cycles and closer alignment with customer production workflows, not merely more container volume.

Restraints and industry response

• Glass vials and ampoules remain central to injectables, but breakage, particle risk, and container-closure integrity concerns raise the effective cost of use.
• FDA CGMP expectations treat container and closure performance as a manufacturing quality issue rather than a downstream packaging concern.
• Sterile packaging requires validated materials, controlled manufacturing environments, and testing that can be hard to amortize in low-price generic and OTC campaigns.
• The constraint is most acute where drug procurement is price regulated or where manufacturers run shorter production campaigns.
• Brevintel analysis indicates the principal tension is between rising specification requirements and customers' need to control total delivered drug cost.
• Serialization, RTU conversion, and more demanding injectable applications raise the capital, quality-system, and technical-service threshold for suppliers.
• Gerresheimer completed its acquisition of Bormioli Pharma in December 2024, adding pharmaceutical glass, plastic, rubber, and closure capabilities.
• Amcor completed its combination with Berry Global in April 2025, broadening healthcare packaging across flexible and rigid formats.

Segmentation Analysis

Packaging type

• Primary packaging is the largest category at $122.07 billion in 2025 (70.4%) and is projected to reach $515.28 billion by 2035 at a 15.60% CAGR.
• Blister packs remain important for solid doses, where unit-dose presentation and barrier selection determine suitability.
• Bottles and containers serve oral solids, liquids, and topical products, with HDPE, PET, polypropylene, and glass selected according to drug and use conditions.
• Vials and ampoules remain central to injectable and lyophilized products; prefilled syringes and cartridges command higher value because they combine containment with patient-use and fill-finish requirements.
• Pouches and sachets address powders, oral liquids, and affordable unit-dose applications, alongside other route-specific containers and delivery components.
• Secondary packaging is projected to grow at 17.10% CAGR, from $34.12 billion in 2025 to $163.82 billion in 2035, as cartons, labels, and leaflets carry identification, safety features, and variable data.
• Trays protect and organize sensitive products in hospital and distribution workflows, converting secondary packs into verification components under DSCSA and EU rules.
• Tertiary packaging is expected to increase from $16.38 billion in 2025 to $65.53 billion by 2035 at a 14.98% CAGR via pallets, corrugated boxes, and stretch wrap and shrink film.

Packaging format

• Rigid packaging generated $97.42 billion in 2025 (56.5%) and is forecast to reach $374.55 billion by 2035 at a 14.52% CAGR.
• Glass vials, bottles, molded plastic containers, and closures remain essential where dimensional stability, sterility, or established qualification history is critical.
• Semi-rigid packaging is projected to increase from $30.48 billion in 2025 to $142.97 billion by 2035 at a 16.82% CAGR.
• Blisters and related formed structures offer unit-dose protection and support patient adherence, particularly in solid-dose therapies.
• Flexible packaging is estimated to grow from $44.67 billion in 2025 to $227.11 billion by 2035 at a 17.76% CAGR, the fastest format rate.
• Pouches, sachets, films, and flow-wrap applications benefit from material efficiency, although pharmaceutical use depends on barrier performance and validated seal integrity.
• Flexible packaging's 17.76% CAGR does not displace rigid and glass systems in high-risk sterile applications where requalification cost outweighs a modest pack-price gap.
• The most attractive growth positions sit where a supplier can match a therapy and route of administration with a proven container, closure, and production-line interface.

Material type

• Plastics include HDPE, PET, PP, PE, and other polymers used in bottles, closures, pouches, droppers, and selected injectable systems, with drug-contact applications requiring compatibility assessment.
• Glass remains closely associated with vials, ampoules, cartridges, and prefilled syringes for parenteral therapies, creating a durable installed base despite fragility.
• Handling requirements support interest in polymer alternatives for selected sensitive formulations even while glass retains its regulatory and technical profile.
• Aluminum is used in blister lidding, cold-form packs, tubes, and inhalation-related applications where barrier or pressure-containment performance is essential.
• Paper and paperboard support cartons, leaflets, labels, and outer packaging; print quality, dimensional consistency, and anti-tampering integration affect serialization line performance.
• Others include elastomeric closures, specialty coatings, and barrier materials that are commercially important because stopper and plunger performance affects container-closure integrity.

Functionality and drug form

• Conventional packaging continues to serve high-volume oral-solid, OTC, and ambient-stable medicines, while sterile packaging is concentrated in injectable, ophthalmic, and certain inhalation products.
• Child-resistant and tamper-evident packaging remains important in retail and prescription channels, combining patient-protection requirements with usability considerations.
• Serialization packaging is expected to expand rapidly because traceability requirements convert printing, vision inspection, and data connectivity into required production-line capabilities.
• Temperature-controlled packaging supports products whose quality depends on controlled transport conditions, including many biologics and vaccines.
• Solid-dosage packaging is the largest volume application, relying on blisters, bottles, and sachets.
• Liquid and injectable drugs use vials, ampoules, infusion systems, syringes, and cartridges, with higher technical content where sterility or dosing precision is required.
• Biologics and biosimilars are the most value-intensive drug-form opportunity because protein stability, extractables and leachables, and delivery-device compatibility must be assessed for each product.
• Dermal and topical medicines use tubes, pumps, jars, and dispensers; ophthalmic products require containers that manage repeated-use contamination risk or single-dose sterility; pulmonary formats use specialized canisters and devices.

End user

• Pharmaceutical manufacturers represented $79.53 billion in 2025 (46.1%) and are projected to reach $352.83 billion by 2035 at a 16.18% CAGR.
• Their procurement priorities center on supply continuity, regulatory support, and global qualification across oral, injectable, and biologic programs.
• Contract manufacturing is forecast to increase from $32.06 billion in 2025 to $150.17 billion by 2035 at a 16.81% CAGR.
• CDMOs favor standardized, ready-to-fill systems that reduce changeover complexity and support multiple customer programs.
• Hospitals and healthcare facilities use packaging that supports safe handling, dispensing, and sterile administration.
• Retail pharmacies depend on formats that combine dispensing efficiency with child resistance, labeling, and patient communication.
• Brevintel analysis suggests segmentation is increasingly defined by the degree of qualification embedded in a packaging platform.
• Primary packaging remains the largest revenue pool because it interfaces directly with the drug product, while secondary packaging grows faster because serialization turns a carton into a compliance system.

Regional Outlook

North America

• North America was valued at $60.93 billion in 2025 (35.3%) and is projected to reach $270.32 billion by 2035 at a 16.18% CAGR.
• The U.S. accounted for $53.13 billion in 2025 and is expected to grow at 16.55% CAGR, supported by a large specialty-drug market and DSCSA operational requirements.
• Canada generated $7.80 billion in 2025 and is expected to advance at a 13.31% CAGR.
• Regional value density is supported by demand for high-specification injectable packaging, delivery systems, and serialized packs.
• Western markets reward technical service, quality documentation, and premium sterile platforms more than converted-material volume.
• Brevintel analysis views North America as a high packaging-value-per-unit region because regulation, biologics demand, and established fill-finish infrastructure favor qualified containment.

Europe

• Europe is projected to grow from $47.63 billion in 2025 to $190.36 billion by 2035 at a 14.97% CAGR.
• The Falsified Medicines Directive provides a common compliance driver for applicable prescription-medicine packaging.
• Germany, valued at $10.42 billion in 2025, is expected to grow at 14.19% CAGR.
• The UK, at $6.64 billion, is expected to grow at 13.61% CAGR.
• France, at $7.40 billion, is expected to grow at 12.93% CAGR.
• Spain, at $5.00 billion, is expected to grow at 16.02% CAGR, the fastest among the named European countries.
• Italy, at $6.05 billion, is expected to grow at 14.69% CAGR; Russia is included within Rest of Europe.
• The region combines mature pharmaceutical demand with a strong base of glass, containment, and drug-delivery suppliers.

Asia Pacific, Latin America, and Middle East & Africa

• Asia Pacific is forecast to expand from $48.29 billion in 2025 to $226.22 billion by 2035 at a 16.81% CAGR, the highest among the major regions.
• China, India, Japan, Australia, and South Korea combine domestic medicine demand with expanding manufacturing capacity.
• China and India are particularly consequential because export-oriented generic, biosimilar, and contract-manufacturing activity raises demand for internationally qualified packs.
• Japan remains a high-specification market, while South Korea's biosimilar production and Australia's specialty distribution needs support sterile and temperature-controlled applications.
• Latin America is projected to increase from $9.32 billion in 2025 to $35.17 billion by 2035 at a 14.30% CAGR, with Brazil the largest market, followed by Mexico and Argentina.
• Aptar acquired Brazil-based oral-dosing packaging provider Sommaplast in December 2025, expanding regional capability in closures, droppers, dispensers, and dosing cups.
• The Middle East and Africa market is expected to grow from $6.40 billion in 2025 to $22.56 billion by 2035 at a 13.51% CAGR.
• Saudi Arabia, valued at $2.03 billion in 2025, is projected to grow at 13.93% CAGR; the UAE, at $1.64 billion, at 14.70%; and South Africa, at $1.43 billion, at 12.69%.
• Exchange-rate volatility and procurement cost pressures in Latin America can delay conversion to higher-cost formats, while MEA adoption of premium packaging varies by reimbursement environment.
• Asia Pacific requires qualified containment alongside cost-efficient local production; Latin America and MEA offer growth but with currency exposure and uneven regulatory implementation.

Competitive Landscape

Structure and recent developments

• The market is fragmented across material specialists, drug-delivery companies, converters, and regional manufacturers.
• Amcor plc held 3.46% of the market in 2025 and led with over 3.5% share, followed by Gerresheimer AG at 2.73%, Schott AG at 1.82%, West Pharmaceutical Services Inc. at 1.47%, and AptarGroup Inc. at 0.68%.
• The top five players collectively held a market share of 10.2% in 2025.
• Few suppliers hold comparable positions across glass containment, elastomeric closures, flexible films, labels, cartons, and drug-delivery devices.
• Amcor strengthened healthcare and multi-material capability through the April 2025 combination with Berry Global, strongest in flexible and rigid applications where scale and conversion capability matter.
• Gerresheimer supplies pharmaceutical glass, plastic, closure, and drug-delivery components; its December 2024 Bormioli Pharma acquisition broadened European primary-packaging supply.
• Schott participates through SCHOTT Pharma, focused on glass and polymer containment, vials, ampoules, cartridges, and prefillable syringe systems, including the October 2024 Alliance for RTU.
• West Pharmaceutical Services specializes in elastomeric components, seals, plungers, and injectable-drug delivery; AptarGroup focuses on dosing and dispensing, including the December 2025 Sommaplast acquisition in Brazil.
• Nipro launched D2F glass vials in October 2024 using Stevanato Group EZ-fill technology, supplied pre-washed, depyrogenated, and sterilized in a nest-and-tub configuration.

Integrated producers

• Amcor plc
• Gerresheimer AG
• Schott AG
• AptarGroup, Inc.
• Becton Dickinson

Specialty suppliers

• West Pharmaceutical Services, Inc.
• Stevanato Group
• SGD Pharma
• Nipro Corporation